Handbook of Cannabis and Related Pathologies
Chapter 99 - Potential Medical Uses of Cannabigerol: A Brief Overview
References (0)
Cited by (22)
Cannabis sativa L. in the cosmeceutical industry: prospects and biotechnological approaches for metabolite improvement
2023, South African Journal of BotanyCannabis: Chemistry, extraction and therapeutic applications
2022, ChemosphereCitation Excerpt :Unlike CBGA, CBG does not undergo any catalytic conversion into other cannabinoids due to the absence of the carboxyl group (–COOH) (Taura et al., 2007). CBG is effective in the treatment of inflammatory bowel disease, bladder dysfunction, Huntington's disease, tumors and certain types of cancers in animal studies (Borrelli et al., 2013; Valdeolivas et al., 2015; Pagano et al., 2015; Deiana, 2017). Furthermore, CBG shows several instances of anti-bacterial activities and has been tested on relieving muscle contractions.
Industrial hemp breeding and genetics
2022, Industrial Hemp: Food and Nutraceutical ApplicationsAnticancer agents based on Plastoquinone analogs with N-phenylpiperazine: Structure-activity relationship and mechanism of action in breast cancer cells
2021, Chemico-Biological InteractionsCitation Excerpt :Their role in apoptosis, cell cycle arrest, and cell migration, etc. has also been well studied [42]. Natural cannabinoids [43], their metabolites [44], and synthetic cannabinoid analogs [45] have also been reported to have antiproliferative activity. Considering the structural similarity of PQ11 with HU331 and its activity profile, we hypothesize that the putative target for PQ11 could be CB2.